Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3b Open-label Tolvaptan Trial in Infants with Autosomal Recessive Polycystic Kidney Disease
2020-005991-36Phase 3Active
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of tolvaptan in autosomal recessive polycystic kidney disease (ARPKD), sponsored by Otsuka Pharmaceutical Development & Commercialization. Primary endpoint: Need for renal replacement therapy by 1 year of age. Started May 2021; status: active.
02
Drugs
tolvaptan
03
Conditions
autosomal recessive polycystic kidney disease (ARPKD)
Beyond the preview
Go deeper on 2020-005991-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005991-36.